Women's Health ChicagoBook a consultation
Menu
Call 847-485-1717

Journal-based research summary · Skin & aesthetics

Spironolactone for adult acne: what the SAFA trial found

A patient guide to a randomized acne trial, including the timing of results and limits of applying them to your care.

Published October 25, 2026 · Sources checked October 25, 2026

What the publication found

The 2023 SAFA trial randomized 410 adult women with persistent facial acne to spironolactone or placebo; 342 contributed to the primary analysis. Participants could continue topical treatments. Differences favoring spironolactone were larger at 24 weeks than at 12 weeks. At 24 weeks, 82% in the spironolactone group reported improvement compared with 63% in the placebo group. Headaches were reported more often with spironolactone, 20% versus 12%. No serious adverse reactions were reported in this trial. Source: Effectiveness of spironolactone for women with acne vulgaris (SAFA) in England and Wales: pragmatic, multicentre, phase 3, double blind, randomised controlled trial.

What the evidence cannot establish

The study involved adult women with acne judged to warrant oral antibiotics, so it does not represent every person with acne. A lack of serious reactions in one trial is not proof that a medicine is risk-free. The results do not diagnose a hormonal cause for an individual’s acne, compare every available treatment, or establish suitability without clinical assessment. Source: Effectiveness of spironolactone for women with acne vulgaris (SAFA) in England and Wales: pragmatic, multicentre, phase 3, double blind, randomised controlled trial.

Give a treatment history enough detail to be useful

Before an acne consultation, list products and prescriptions, how long you used each, and why you continued or stopped. If you have dated photographs, consider bringing them to help explain changes over time. Describe what matters most to you, such as visible breakouts or how acne affects daily life, without assuming that one treatment should solve every concern.

Ask about the timing of assessment

This trial is a reminder to notice when researchers measured an outcome. Ask a clinician when a proposed treatment would be reviewed and what changes they would look for. Also ask what symptoms or problems should prompt earlier contact. Do not use a research timeline as an instruction to start, stop, or continue a medicine without advice.

A prescription discussion, not a cosmetic promise

Bring questions about the possible benefits, safety assessment, follow-up, and alternatives. Ask whether your concerns need medical acne treatment, a different evaluation, or another type of care. Women’s Health Chicago’s acne page is a starting point for a Palatine consultation request. This guide does not promise a spironolactone prescription or establish that the studied approach fits your circumstances.

Questions to bring to your visit

  • Does my acne resemble the condition studied in this trial?
  • What individual safety considerations need review?
  • When should we assess progress, and when should I contact the clinician sooner?

Sources and further reading

  1. Effectiveness of spironolactone for women with acne vulgaris (SAFA) in England and Wales: pragmatic, multicentre, phase 3, double blind, randomised controlled trial.Journal publication · Peer-reviewed randomized trial. 2023

This is a patient-facing guide, not an original research publication. Prepared with AI assistance and checked against the linked sources. No clinician review is claimed. General education cannot determine which care is right for you.